Key Highlights

  • Akanda received a Nasdaq notification on June 16 for failing to meet the minimum $2.5 million stockholders' equity requirement, with the company reporting stockholders' equity of negative $11.99 million for fiscal year 2025.
  • The company has until July 31, 2026 to submit a compliance plan, with Nasdaq able to grant up to 180 days for remedy if the plan is accepted, though the company does not meet alternative compliance standards via market cap or net income either.
  • AKAN is trading at $15.88 pre-market June 22, down 12.75% from the June 18 close of $18.20, against a 52-week range of $2.30 to $209.23 reflecting extreme post-reverse-merger price volatility.

A Nasdaq Compliance Crisis Drives the Decline

Akanda Corp. (NASDAQ: AKAN) is trading at $15.88 pre-market June 22, down 12.75% from the June 18 close of $18.20. Akanda is an international medical cannabis and wellness platform company engaged in the cultivation, manufacture, and distribution of cannabis-based products through subsidiaries including CanMart, a UK-licensed pharmaceutical importer and distributor, alongside First Towers and Fiber Corp., a wholly-owned subsidiary operating a 700-kilometre-plus fibre optic network in Mexico.

The catalyst for the decline is the Nasdaq notification letter received June 16, confirming the company is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders' equity for continued listing on the Nasdaq Capital Market. Akanda reported stockholders' equity of negative $11,990,437 in its 2025 Annual Report, a deficit of approximately $14.5 million below the required threshold. Nasdaq also determined that the company does not meet the alternative continued listing standards relating to market value of listed securities or net income from continuing operations, closing both alternative compliance pathways.

The notification has no immediate effect on listing status. Akanda has 45 calendar days, until July 31, 2026, to submit a compliance plan. If Nasdaq accepts the plan, an extension of up to 180 days from the June 16 notice date may be granted for the company to regain compliance. The company has stated it intends to submit a plan and is evaluating alternatives to restore the required equity position.

Valuation and Risk Considerations

AKAN's market capitalisation stands at approximately $589,000, an exceptionally small figure for a listed company. The EPS of negative $15,283.89 and the 52-week range of $2.30 to $209.23 reflect the post-reverse-merger capital structure distortion. Key risks include the inability to raise sufficient equity capital to cure the stockholders' deficit, the discretionary nature of Nasdaq's compliance plan acceptance, and the operational challenges of the cannabis and fibre optic subsidiaries.

Conclusion

Akanda's pre-market decline is a direct market response to confirmed Nasdaq non-compliance. The near-term focus is the July 31 deadline for submitting a compliance plan that Nasdaq will find credible.